6muf

Publication Abstract from PubMed

Diverse entry inhibitors targeting the gp120 subunit of the HIV-1 envelope (Env) trimer have been developed including BMS-626529, also called temsavir, a prodrug version of which is currently in phase III clinical trials. Here we report the characterization of a panel of small-molecule inhibitors including BMS-818251, which we show to be >10-fold more potent than temsavir on a cross-clade panel of 208-HIV-1 strains, as well as the engineering of a crystal lattice to enable structure determination of the interaction between these inhibitors and the HIV-1 Env trimer at higher resolution. By altering crystallization lattice chaperones, we identify a lattice with both improved diffraction and robust co-crystallization of HIV-1 Env trimers from different clades complexed to entry inhibitors with a range of binding affinities. The improved diffraction reveals BMS-818251 to utilize functional groups that interact with gp120 residues from the conserved beta20-beta21 hairpin to improve potency.

Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry.,Lai YT, Wang T, O'Dell S, Louder MK, Schon A, Cheung CSF, Chuang GY, Druz A, Lin B, McKee K, Peng D, Yang Y, Zhang B, Herschhorn A, Sodroski J, Bailer RT, Doria-Rose NA, Mascola JR, Langley DR, Kwong PD Nat Commun. 2019 Jan 3;10(1):47. doi: 10.1038/s41467-018-07851-1. PMID:30604750^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.